Archives
- 2026-08
- 2026-07
- 2026-06
- 2026-05
- 2026-04
- 2026-03
- 2026-02
- 2026-01
- 2025-12
- 2025-11
- 2025-10
- 2025-09
- 2025-03
- 2025-02
- 2025-01
- 2024-12
- 2024-11
- 2024-10
- 2024-09
- 2024-08
- 2024-07
- 2024-06
- 2024-05
- 2024-04
- 2024-03
- 2024-02
- 2024-01
- 2023-12
- 2023-11
- 2023-10
- 2023-09
- 2023-08
- 2023-07
- 2023-06
- 2023-05
- 2023-04
- 2023-03
- 2023-02
- 2023-01
- 2022-12
- 2022-11
- 2022-10
- 2022-09
- 2022-08
- 2022-07
- 2022-06
- 2022-05
- 2022-04
- 2022-03
- 2022-02
- 2022-01
-
PKH26 Red Fluorescent Cell Linker Kit Guide
2026-08-29
The PKH26 Red Fluorescent Cell Linker Kit supports red fluorescent labeling of cell membrane lipid regions for cell tracing and proliferation-oriented assays. It is intended for membrane labeling in in vitro and in vivo workflows, not for intracellular targets or non-membrane labeling, and exact labeling conditions should be established from the kit instructions and cell-specific optimization.
-
HyperScript RT SuperMix for qPCR in PDAC Research
2026-08-28
Translate PDAC cell-fate changes into reproducible qRT-PCR readouts with a thermally stable reverse transcriptase, mixed-primer initiation, and high RNA-input flexibility. The workflow is especially useful for tracking adipogenic conversion, EMT suppression, and low-abundance transcripts from limited samples.
-
SAG and Embryonic Hedgehog Signaling
2026-08-28
SAG is a selective Smoothened receptor agonist for dissecting Hedgehog pathway behavior across developmental and regenerative models. This article explains how dose, developmental timing, and endpoint selection determine whether SAG reveals pathway biology, supports repair studies, or produces malformation phenotypes.
-
Site-Specific PEGylation of IL-11 in Pulmonary Fibrosis
2026-08-27
A 2024 International Journal of Pharmaceutics study engineered IL-11 variants that retain IL-11Rα binding while selectively weakening GP130 engagement through site-specific PEGylation. The resulting receptor-biased analogs extended IL-11 exposure and reduced bleomycin-induced pulmonary fibrosis in mice, providing a useful framework for cytokine antagonist design.
-
IWP-2: Context-Aware PORCN Inhibition
2026-08-27
IWP-2 is a potent Wnt production inhibitor for dissecting ligand-dependent pathway biology in cancer research. This article pairs PORCN pharmacology with cell-state-resolved assay logic to improve interpretation beyond routine proliferation and apoptosis measurements.
-
Anti-HMGB1 Rabbit Monoclonal Antibody Guide
2026-08-26
The Anti-HMGB1 Rabbit Monoclonal Antibody, SKU MA3057, provides an affinity-purified reagent for detecting HMGB1 in human, mouse, and rat samples by Western blot, immunohistochemistry, and flow cytometry. It is for controlled research workflows only and should not be used for diagnosis, therapy, or unvalidated live-cell applications.
-
SAR405 and the Energy Logic of Autophagy
2026-08-26
A mechanistic and translational framework for using SAR405, a selective Vps34 inhibitor, to resolve how energy stress, AMPK–ULK1 signaling, autophagy inhibition, vesicle trafficking modulation, and lysosome function impairment intersect in research and cancer models.
-
BV6: A Causal Assay Framework for IAP Biology
2026-08-25
BV6 is an IAP antagonist that helps researchers interrogate apoptosis, treatment sensitization, and disease-model responses. This guide adds a distinct assay-interpretation framework informed by mitochondrial apoptosis research, separating pathway engagement from phenotypic rescue.
-
EdU Imaging Kits (Cy3) for Organoid Studies
2026-08-25
EdU Imaging Kits (Cy3) combine denaturation-free click chemistry with bright Cy3 readouts for quantifying S-phase DNA synthesis in cells and patient-derived organoids. The workflow is especially useful for testing drug effects in cancer-associated fibroblast–tumor models while preserving morphology and downstream antigen accessibility.
-
Cell Counting Kit-8 for Wound Hydrogel Research
2026-08-24
See how CCK-8 converts viable-cell metabolism into a practical readout for evaluating regenerative hydrogels, photothermal treatments, and biomaterial safety. This workflow emphasizes controls that separate true cytotoxicity from optical interference, heat stress, and three-dimensional matrix effects.
-
Berberine, Tuft Cells, and Estrogen-Deficient Bone Loss
2026-08-24
The reference study identifies a gut–bone axis mechanism in which berberine increases intestinal butyrate, activates GPR41-associated signaling, and expands tuft cells to improve barrier integrity and osteoimmune balance. Its ovariectomy, microbiome, immune, genetic, and organoid experiments provide a mechanistic framework for investigating postmenopausal bone loss, while remaining preclinical.
-
MAPK10–KRT16 Axis in NSCLC Metastasis
2026-08-23
The reference study identifies MAPK10 as a metastasis-suppressing kinase that phosphorylates KRT16 at Ser356 and Ser397, enabling RNF213-mediated ubiquitination and proteasomal degradation. Its integrated cellular, animal, and clinical evidence positions the MAPK10/KRT16/RNF213 axis as a mechanistic framework for studying NSCLC dissemination and as a candidate prognostic pathway.
-
IWP-2 Workflow for Wnt Signaling Assays
2026-08-22
Build more informative Wnt pathway experiments with IWP-2, from soluble stock preparation through proliferation, apoptosis, and high-content morphology readouts. This workflow connects PORCN inhibition with the morphology-first strategy of a cardiomyocyte profiling study while clearly separating established product data from exploratory applications.
-
CD44 Metabolic Rewiring in IDH-Mutant Leukemia
2026-08-22
The reference study identifies CD44 as a functional metabolic dependency of IDH-mutant leukemia, linking adhesion signaling to pentose phosphate pathway activity, NADPH production, and sustained R-2HG synthesis. Its isogenic CRISPR-based design supports combination strategies that pair mutant-IDH inhibition with CD44-directed interventions while highlighting important questions about disease heterogeneity and therapeutic selectivity.
-
Tamoxifen Workflows for CreER and Cancer Research
2026-08-21
Tamoxifen combines selective estrogen receptor modulation with practical utility as a temporal trigger for CreER-mediated gene knockout. This guide connects controlled gene deletion workflows with the mitochondrial iron findings of a recent PINK1 colorectal cancer study, while emphasizing formulation, controls, and troubleshooting.